Bavarian Nordic

Bavarian Nordic names **Tarja Stenvall** as its new President and Chief Executive Officer, replacing **Paul Chaplin**. The transition takes effect on **October 15**, following Chaplin’s announced departure earlier this year. Stenvall brings leadership experience to the biotech firm specializing in vaccines and immunotherapies.

Sep 2026NLSNews article

Bavarian Nordic names **Tarja Stenvall** as its new President and Chief Executive Officer, replacing **Paul Chaplin**. The transition takes effect on **October 15, 2026**, following Chaplin’s announced departure earlier this year. Stenvall’s appointment follows the company’s focus on leadership continuity amid its biopharmaceutical operations.

Sep 2026bavarian-nordic.comNews article

Bavarian Nordic A/S reports strong financial performance for the first half of 2026, detailing interim results and business progress. The company also releases its financial calendar for 2027, outlining upcoming reporting dates and investor updates. The announcement highlights continued operational momentum in its biopharmaceutical portfolio.

Aug 2026BioSpaceNews article

Bavarian Nordic introduces its **Vimkunya** vaccine for **chikungunya** in the UK, targeting individuals aged **12 and older**. The vaccine marks the company’s first approved chikungunya immunization for this demographic. Regulatory approvals and distribution details were not specified in the announcement.

Sep 2025manufacturingchemist.comNews article